Company news

Shield Therapeutics PLC news in 2022

Shield Therapeutics PLC's news releases, calls and decks from 2022, newest first.

View company

Publication of Circular &Notice of General Meeting

December 16, 2022

Successful completion of US$18.5m Equity Fundraise

December 13, 2022

Republic of Korea update

October 31, 2022

Shelf-life for Accrufer® extended to 48 months

October 27, 2022

Data presented at ACG Annual Scientific Meeting

October 24, 2022

Hardman & Co Research on Shield Therapeutic...

September 15, 2022

Half-year Report

September 8, 2022

Launch of new corporate brand and website

September 1, 2022

Notice of Interim Results

August 31, 2022

Hardman & Co: Q&A on Shield Therapeutic...

August 12, 2022

Grant of share options

August 9, 2022

Completion of Loan Agreement & Partial Conversion

August 1, 2022

Results of 2022 General Meeting

July 27, 2022

Shield Therapeutics (STX): Looking to accelerat...

July 26, 2022

New Drug Submission accepted by Health Canada

July 14, 2022

Notice of General Meeting

July 8, 2022

2021 Annual Report and 2022 AGM Notice

June 30, 2022

KYE Pharmaceuticals Files Accrufer® NDS in Canada

March 21, 2022

Shield Therapeutics (STX) - PBMs have bought in...

March 2, 2022

Investor Presentation

February 25, 2022

KOL Investor Event on Iron Deficiency

February 4, 2022

Licence Agreement in Canada for Accrufer®

January 5, 2022

Calls in 2022

Decks in 2022